MAP, SHMAP... A systolic target makes more sense in cardiogenic shock
Miller, Elliott
(
Yale University
, New Haven , Connecticut , United States )
Berg, David
(
Brigham and Womens Hospital
, Boston , Massachusetts , United States )
Author Disclosures:
Elliott Miller:DO NOT have relevant financial relationships
| David Berg:DO have relevant financial relationships
;
Research Funding (PI or named investigator):AstraZenea:Active (exists now)
; Other (please indicate in the box next to the company name):CEC - CeleCor Therapeutics:Active (exists now)
; Other (please indicate in the box next to the company name):CEC - Beckman Coulter:Active (exists now)
; Other (please indicate in the box next to the company name):CEC - Novo Nordisk:Active (exists now)
; Other (please indicate in the box next to the company name):CEC - Tosoh Biosciences:Active (exists now)
; Other (please indicate in the box next to the company name):CEC - Kowa Pharmaceuticals:Past (completed)
; Speaker:USV Private Limited:Past (completed)
; Speaker:Pri-Med:Past (completed)
; Speaker:Metabolic Endocrine Education Foundation:Past (completed)
; Consultant:Youngene Therapeutics:Past (completed)
; Consultant:Pfizer:Active (exists now)
; Consultant:AstraZeneca:Active (exists now)
; Research Funding (PI or named investigator):Merck:Active (exists now)
; Research Funding (PI or named investigator):Pfizer:Active (exists now)